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Regular Papanicolaou (Pap) testing has been the backbone of the 
most successful cancer reduction program in the public health 
system. However, it is not perfect. In high-income countries, more 
than half of the women who are diagnosed with cervical cancer had 
never had a Pap test or were infrequently screened (1). In the 
United Kingdom, recent studies have suggested a decline in the 
routine screening program participation to below its target rate of 
80%, particularly among women aged 25–29 years (2). Factors that 
may discourage women from going for regular screening are lack of 
time, discomfort, inconvenience, cultural objections, and poor 
socioeconomic status. In low-resource regions, additional barriers 
include lack of knowledge and lack of accessible or appropriate 
screening facilities as well as the prohibitively high cost of 
screening. Offering a simple, inexpensive, and convenient self-test 
that respects individual privacy may improve the participation of 
women who might be otherwise reluctant to undergo screening and 
those who live in areas with poor access to health care.
In the last few years, we have learned that self-collected vaginal 
specimens from women who have received appropriate instruction 
produce human papillomavirus (HPV) test results similar to 
cervical specimens collected by health-care professionals (3). This 
congruence has supported the concept of introducing HPV self-
sampling (Self-HPV) as an alternative means for cervical cancer 
screening. However, screening is a complex process, and the intro-
duction of a new screening scenario should be carefully evaluated. 
Fundamental issues that must be addressed regarding the future of 
Self-HPV as a primary screening method are 1) whether the per-
formance for the detection of cervical intraepithelial neoplasia 
(CIN) grade 2–3 and cervical cancer (CIN2+) by Self-HPV is (at 
least) equal or superior to that of the Pap test, 2) whether screening 
participation rate with Self-HPV will be sufficiently high, and 3) 
whether comparable results would be obtained outside a research 
setting.
In this issue of the Journal, Zhao et al. (4) have addressed the 
first issue. In a pooled analysis of data from five population-based 
cervical cancer screening studies, including a total of 13 140 rural 
Chinese women aged 17–56 years, the investigators demonstrated 
the feasibility of a Self-HPV approach in a context of primary 
screening. Women were successively screened with Self-HPV, 
visual inspection with acetic acid (VIA), physician-collected cer-
vical specimens for HPV testing (Physician-HPV), and liquid-
based cytology (LBC). Overall 15.6% of Self-HPV and 14.7% of 
Physician-HPV tests were HPV positive (91.8% agreement, 95% 
confidence interval [CI] = 84.9% to 95.7%). The clinical sensi-
tivity and specificity with which Self-HPV detected CIN2+ were 
86.2% (95% CI = 82.9% to 89.1%) and 80.7% (95% CI = 75.6% 
to 85.8%), respectively, and the corresponding values for LBC 
were 80.7% (95% CI = 77.0% to 84.0%) and 94.0% (95% 
CI = 92.2% to 95.8%), respectively. Overall, this study supports 
the conclusions that Self-HPV testing is more sensitive than LBC 
for the detection of CIN2+ and that performance does not depend 
on the age of the women being screened. These data add to a 
recent randomized trial in which Self-HPV was demonstrated to 
be 3.4 times more sensitive than the Pap test in detecting CIN2+ 
in Mexican women of low socioeconomic status (5).
The problem with Self-HPV is its specificity. A total of 15.6% 
of the women screened HPV-positive and were referred to colpos-
copy by the investigators. This approach is impractical in the 
context of routine screening without triage of HPV-positive 
women to colposcopy by a more specific test. A randomized trial 
(6) demonstrated that primary HPV screening with triage by con-
ventional cytology was more sensitive than the Pap test. This 
strategy is probably one of the most promising for countries that 
have cytology-based screening programs. Another study (7) 
showed that triennial primary home-based Self-HPV screening 
followed by in-clinic cytology triage was sufficiently accurate and 
cost effective. For countries with a poorly developed cytology-
based screening program, VIA may be the more appropriate 
strategy. It has the advantage to provide immediate results, making 
it possible to triage and treat without delay during the same visit. 
Zhao et al. (4) explored both triaging systems and calculated that 
Self-HPV testing coupled with LBC reduced the referral rate to 
4.8% (95% CI = 3.3% to 6.7%) and Self-HPV testing with VIA 
reduced referrals to 4.5% (95% CI = 3.3% to 6.1%).
Although not evaluated in this study, assessment of women’s 
interest and willingness is crucial before introducing a new 
screening method. It is unclear if the results obtained by Zhao 
et al. (4) will be reproducible among patients with limited educa-
tion and nonuniform instructions about self-sampling technique. 
An earlier study on patient acceptance in rural China (8) reported 
that the major barrier encountered was related to the women’s 
educational level. Women generally are receptive to Self-HPV as 
part of future screening, but many of them are concerned about 
doing the test properly and have greater confidence in clinician 
sampling (9–11). Efforts are still needed to increase awareness 
about HPV and cervical cancer, and more information is needed 
about the reliability of the method.
The participation rate of women and cost-effectiveness of 
home-based self-sampling also need to be assessed. In countries 
with opportunistic screening, few data are currently available. 
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Studies in Western countries with organized screening programs 
(12–14) reported that providing self-sampling kits to women who 
did not participate, particularly when in addition to a reminder 
letter, may improve their screening adherence. Nevertheless,  
further investigation is needed to evaluate the response to self-
sampling and its cost-effectiveness in different demographic and 
geographic settings (14). An Italian study (15) found that the effec-
tiveness of mailing self-samplers to nonresponders was context 
specific and might be expensive in terms of number of Self-HPV 
tests used per screened woman.
Current literature reinforces the increasing body of evidence 
that self-collected samples for HPV DNA testing may be an appro-
priate strategy to increase participation of unscreened women and 
ultimately promote a decrease in incidence of and mortality from 
cervical cancer. However, the feasibility and impact of introducing 
this method outside research settings requires further evaluation. 
Research should also assess the availability of validated devices and 
the quality of patient education. Health-care professionals should 
provide sufficient support to participants to properly interpret 
their test results, thus avoiding any delay to follow-up and treat-
ment. Self-HPV per se is only a part of a secondary prevention 
program, and obstacles to program participation might not only 
result in program failure but also be harmful for women.
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